Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks
Hepatitis C virus dried on inanimate surfaces can remain infectious for up to six weeks
Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure
Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes
After diagnosis of hepatitis C, some gay men willing to consider risk-reduction practices
Ritonavir the cause of the interaction between telaprevir and ritonavir-boosted atazanavir
Faldaprevir safe and effective in HCV treatment-experienced patients
AbbVie reports 96% cure rate for interferon-free hepatitis C regimen in phase 3 study
Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated
